Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 51407-661

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 51407-661). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-661-30 (51407 661 30)

51407-661-30 (51407 661 30)
This is a medication with NDC code 51407-661-30. It contains extended-release tablets that come in a bottle of 30 tablets. Each tablet is film-coated and contains 4 mg of fesoterodine fumarate. The medication should be stored at room temperature, protected from moisture, and kept out of reach of children. Patients should not chew, divide, or crush the tablets, and the appropriate dosage should be determined by a healthcare professional. The patient information can be found on https/igsms.usi and must be dispensed by the pharmacist. Manufactured by Dr. Reddy’s Laboratories Limited and marketed by GSMS, Incorporated. Last revised in July 2022.*
FDA Label Image

51407-662-30 (51407 662 30)

51407-662-30 (51407 662 30)
NDC 51407-862-30 is a medication called Ghicccomiamerosaorcane Fumarate. It is available in extended-release tablets containing 8mg of Fumarate. Dosage instructions can be found in the accompanying Prescribing Information. The medication should be swallowed whole and not chewed, crushed or divided. It should be kept protected from moisture at 20° - 25°C (68° - 77°F). The medication should be kept out of reach of children. Patient information can be printed at https://gsms.us/. This medication is manufactured by Dr. Reddy's Laboratories Limited and marketed by GSMS, Incorporated in Camarillo, CA 93012 USA. This information is only for the pharmacist for dispensing and does not include a useful description for the general public.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
This is a description of a study that measured the change in the number of micturitions (urinations) per 24 hours in participants taking a medication called Fesoterodine fumarate 4mg. The study involved 279 participants and lasted for 12 weeks. The figure provided shows the change in the number of micturitions over time.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
The text is describing a chart or a graph displaying the change in urge incontinence episodes per day over the course of 12 weeks. The chart includes data from a study with a sample size of 211 individuals. The text mentions different time intervals at which data was collected (0, 2, 8, and 12 weeks).*
FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
The text describes a figure that shows the change in urge incontinence episodes per 24 hours over 12 weeks in a study involving 205 participants. The data is presented in a graph and includes data points for weeks 0, 2, 8, and 12. The mean change from baseline is specified.*
FDA Label Image

Logo1 (Logogsms)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.